ArticleEuropean journal of nuclear medicine and molecular imaging2026
Prognostic value of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTrastuzumab deruxtecan (T-DXd) has recently reshaped the management of HER2-low metastatic breast cancer. While pivotal trials relied on CT-based RECIST 1.1, [
methodsThis retrospective study included all HER2-low metastatic breast cancer patients treated with T-DXd between 2022 and 2025 at the Strasbourg Europe Cancer Institute (ICANS) who underwent [
resultsForty-three patients were included. Baseline SULpeak of the most hypermetabolic lesion was an independent prognostic factor for OS, mPFS and TTT (p < 0.05). A ROC-derived cutoff of 6 identified two prognostic groups, with SULpeak < 6 associated with significantly improved outcomes. Early metabolic response was also linked to longer OS and PFS (p< 0.05), with median PFS of 9.2 vs. 4.2 months (HR 2.67; 95% CI 1.30-5.47). Combining baseline SULpeak and metabolic response (complete or partial metabolic response) defined three risk groups with significantly different OS and PFS.
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.